BioMarin Pharmaceuticals
BMRN
418 hedge funds and large institutions have $14.8B invested in BioMarin Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 160 increasing their positions, 133 reducing their positions, and 47 closing their positions.
32% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 47
20% more repeat investments, than reductions
Existing positions increased: 160 | Existing positions reduced: 133
6% more capital invested
Capital invested by funds: $14B → $14.8B (+$809M)
9% more call options, than puts
Call options by funds: $82.3M | Put options by funds: $75.7M
1% more funds holding
Funds holding: 414 → 418 (+4)
0.69% less ownership
Funds ownership: 98.49% → 97.8% (-0.69%)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$971M |
| 2 |
Primecap Management
Pasadena,
California
|
+$73.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$72.3M |
| 4 |
Jennison Associates
New York
|
+$56.1M |
| 5 |
ClearBridge Investments
New York
|
+$46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$91.7M |
| 2 |
HM
HealthCor Management
New York
|
-$64.2M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$46.5M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$44.4M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$37M |
BMRN Hedge Fund Activity: Q1 2017 in Review
418 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q1 2017, worth a combined $14.8B — up 5.8% from $14B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new BMRN positions and 47 closed out — a net gain of 15 holders — while 160 added to existing stakes and 133 trimmed.
The largest buyer was BlackRock, adding an estimated $971M. The largest seller was JP Morgan Chase, cutting an estimated $91.7M.
- 418 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q1 2017, up from 414 in Q4 2016.
- Funds reported $14.8B of BioMarin Pharmaceuticals stock for Q1 2017, up 5.8% quarter-over-quarter.
- 62 funds opened new BioMarin Pharmaceuticals positions in Q1 2017 and 47 closed out, a net change of +15 holders.
- The largest BioMarin Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $971M added.
- The largest BioMarin Pharmaceuticals seller in Q1 2017 was JP Morgan Chase, an estimated $91.7M sold.
Based on aggregated 13F filings for Q1 2017.